Shanghai Fosun Pharmaceutical's (HKG:2196, SHA:600196) attributable profit fell to 1.22 billion yuan in the first half from 1.78 billion yuan in the year-ago period, according to a Tuesday filing with the Hong Kong Stock Exchange.
Earnings per share at the drug company decreased to 0.46 yuan from 0.67 yuan a year earlier. Analysts at Visible Alpha estimated EPS at 0.55 yuan.
Revenue declined to 20.4 billion yuan from 21.3 billion yuan in the previous year. Visible Alpha analysts forecast revenue at 21.3 billion yuan.
Price (HKD): $12.54, Change: $+0.12, Percent Change: +0.97%
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments